Gan & Lee Pharmaceuticals.
603087
Rangering i aksjer
#3007
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aksjekurs
$10.03
Markedsverdi
$5.99B
Endring (1 dag)
-3.71%
Endring (1 år)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
Aksjeprishistorikk for Gan & Lee Pharmaceuticals. (603087)
Høyeste sluttskurs: $10.28 den 2026-10-01
Laveste sluttskurs: $9.67 den 2020-06-01
Laveste sluttskurs: $9.67 den 2020-06-01
Aksjeprishistorikk for Gan & Lee Pharmaceuticals. fra 2020 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 0.50% |
| 2025 | 49.04% |
| 2024 | -17.59% |
| 2023 | 56.66% |
| 2022 | -56.78% |
| 2021 | -39.34% |
| 2020 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $440.58 | -16.40% |
US
|
|
| $197.82 | -45.30% |
FR
|
|
| $170.48 | 12.48% |
JP
|
|
| $198.36 | 34.12% |
US
|
|
| $70.09 | -8.42% |
CH
|
